TrialsgrambetaRCTs are beautiful

MOSAIC

2004

FOLFOX as Adjuvant Therapy in Stage II/III Colon Cancer

In 2,246 patients with resected stage II/III colon cancer, adjuvant FOLFOX4 improved disease-free survival compared with 5-FU/leucovorin.

Result

Efficacy: 3-year disease-free survivalHR 0.77 · P = 0.002

Below 1 favours FOLFOX4, above 1 favours 5-FU/leucovorin.

Event rates
Absolute difference
5.3 points
NNT
19

Absolute difference and NNT are derived from the event rates.

Also reported: 6-yr OS in stage III 72.9% vs 68.7% (HR 0.80, 95% CI 0.65-0.97, P=0.023); no OS benefit in stage II.

Original publication
Subtopic
Colon adjuvant
Design
Open-label RCT
Relevance
Practice-defining: a trial the field needs to know.
Source
André T, et al. N Engl J Med. 2004;350(23):2343-2351; André T, et al. J Clin Oncol. 2009;27(19):3109-3116.doi 10.1056/NEJMoa032709

Discussion & critique

Established oxaliplatin-based adjuvant therapy in stage III colon cancer. Stage II remains case-by-case, weighted by clinical and molecular risk features.